Loading...
Header Logo
Keywords
Last Name
Institution

Camille Gunderson

Concepts (198)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Genital Neoplasms, Female
8
2018
70
4.650
Why?
Ovarian Neoplasms
12
2018
407
3.880
Why?
Poly(ADP-ribose) Polymerase Inhibitors
4
2018
19
2.410
Why?
Uterine Neoplasms
4
2016
57
2.190
Why?
Neoplasms, Glandular and Epithelial
4
2017
77
1.770
Why?
Retrospective Studies
18
2018
1570
1.640
Why?
Female
34
2018
10165
1.520
Why?
Aged, 80 and over
15
2018
1493
1.500
Why?
Aged
21
2018
3676
1.440
Why?
Neoplasm Recurrence, Local
4
2018
287
1.400
Why?
Middle Aged
23
2018
5071
1.380
Why?
Antineoplastic Agents
6
2018
627
1.320
Why?
Laparoscopy
5
2016
119
1.310
Why?
Adult
22
2018
5272
1.290
Why?
Vaginal Neoplasms
2
2013
11
1.290
Why?
Endometrial Hyperplasia
2
2013
7
1.250
Why?
Hysterectomy
5
2016
69
1.240
Why?
Health Services Accessibility
2
2013
76
1.200
Why?
Patient Selection
3
2018
140
1.180
Why?
Humans
34
2018
18314
1.140
Why?
Clinical Trials as Topic
3
2017
134
1.140
Why?
Endometrial Neoplasms
2
2013
116
1.140
Why?
Obesity
2
2016
354
1.080
Why?
Healthcare Disparities
2
2018
57
1.060
Why?
Carcinoma, Endometrioid
3
2017
37
1.050
Why?
Precision Medicine
2
2018
25
0.980
Why?
Cystadenocarcinoma, Serous
2
2016
28
0.970
Why?
Neutropenia
3
2018
31
0.900
Why?
Clinical Trials, Phase I as Topic
1
2018
15
0.900
Why?
Phthalazines
2
2015
13
0.890
Why?
Piperazines
2
2015
33
0.870
Why?
Antineoplastic Agents, Immunological
1
2018
16
0.870
Why?
Patient Participation
1
2017
34
0.830
Why?
Leiomyomatosis
1
2016
3
0.800
Why?
Vascular Neoplasms
1
2016
4
0.800
Why?
Vena Cava, Inferior
1
2016
14
0.780
Why?
Angiogenesis Inhibitors
1
2018
112
0.780
Why?
Intensive Care Units
1
2016
28
0.780
Why?
Progestins
2
2013
7
0.760
Why?
Genes, BRCA1
1
2015
9
0.750
Why?
Genes, BRCA2
1
2015
10
0.750
Why?
Germ-Line Mutation
1
2015
19
0.750
Why?
Muscle, Smooth, Vascular
1
2016
79
0.750
Why?
Genetic Testing
1
2015
37
0.730
Why?
Uterine Cervical Neoplasms
2
2016
198
0.700
Why?
Sarcoma
1
2014
25
0.660
Why?
Hospitals, High-Volume
1
2013
7
0.660
Why?
Surgery Department, Hospital
1
2013
9
0.660
Why?
Inflammation
1
2016
304
0.650
Why?
Adolescent
8
2017
2208
0.650
Why?
Insurance, Health
1
2013
54
0.630
Why?
Prognosis
6
2016
617
0.630
Why?
Enzyme Inhibitors
1
2015
244
0.630
Why?
Young Adult
7
2018
1790
0.630
Why?
Carcinoma
1
2014
78
0.630
Why?
Venous Thromboembolism
1
2014
77
0.620
Why?
Ambulatory Care
1
2013
60
0.620
Why?
Carcinoma in Situ
1
2013
38
0.610
Why?
Adenocarcinoma, Clear Cell
3
2016
15
0.600
Why?
Hospitalization
1
2013
109
0.600
Why?
Fertility Preservation
1
2012
3
0.590
Why?
Mutation
1
2016
638
0.590
Why?
Genital Diseases, Female
1
2011
1
0.580
Why?
Antineoplastic Agents, Hormonal
1
2012
21
0.580
Why?
Hernia, Umbilical
1
2011
4
0.580
Why?
Neoplasm Staging
6
2016
474
0.570
Why?
Pregnancy Outcome
1
2012
70
0.560
Why?
Age Factors
4
2018
525
0.560
Why?
Follow-Up Studies
5
2016
805
0.540
Why?
Risk Factors
5
2016
1431
0.540
Why?
Postoperative Complications
1
2014
360
0.520
Why?
Gynecologic Surgical Procedures
1
2010
38
0.510
Why?
Treatment Outcome
6
2015
1595
0.490
Why?
Adenocarcinoma
1
2012
273
0.470
Why?
Disease-Free Survival
4
2017
280
0.450
Why?
Lung Transplantation
1
2008
2
0.450
Why?
Enterocolitis, Pseudomembranous
1
2008
16
0.440
Why?
Survival Rate
4
2017
375
0.430
Why?
Cytoreduction Surgical Procedures
2
2017
18
0.420
Why?
Clostridium difficile
1
2008
52
0.410
Why?
Neoplasms, Cystic, Mucinous, and Serous
2
2017
12
0.410
Why?
Molecular Targeted Therapy
2
2018
63
0.400
Why?
Image Processing, Computer-Assisted
2
2018
168
0.390
Why?
Poly(ADP-ribose) Polymerases
2
2015
23
0.370
Why?
Randomized Controlled Trials as Topic
2
2015
187
0.340
Why?
Proportional Hazards Models
2
2014
163
0.330
Why?
Ovariectomy
2
2016
36
0.330
Why?
Risk Assessment
2
2018
419
0.330
Why?
Body Mass Index
2
2016
289
0.320
Why?
Chemotherapy, Adjuvant
3
2017
98
0.310
Why?
Neoadjuvant Therapy
2
2017
34
0.260
Why?
Kaplan-Meier Estimate
3
2016
165
0.260
Why?
Neoplasm Grading
3
2016
89
0.250
Why?
Oklahoma
2
2014
848
0.250
Why?
Cohort Studies
2
2018
614
0.230
Why?
Health Equity
1
2018
1
0.230
Why?
Proteinuria
1
2018
7
0.230
Why?
Epistaxis
1
2018
5
0.220
Why?
Nausea
1
2018
10
0.220
Why?
Vomiting
1
2018
10
0.220
Why?
Headache
1
2018
16
0.220
Why?
Water-Electrolyte Imbalance
1
2018
5
0.220
Why?
Intestinal Perforation
1
2018
12
0.220
Why?
Anemia
1
2018
21
0.220
Why?
Fatigue
1
2018
30
0.220
Why?
Bevacizumab
1
2018
61
0.220
Why?
Diarrhea
1
2018
48
0.220
Why?
Sulfonamides
1
2018
43
0.210
Why?
Pyrimidines
1
2018
89
0.200
Why?
Hemorrhage
1
2018
131
0.200
Why?
Carcinosarcoma
1
2016
16
0.200
Why?
Autoimmune Diseases
1
2018
130
0.200
Why?
Antineoplastic Combined Chemotherapy Protocols
2
2017
306
0.200
Why?
Syndrome
1
2016
58
0.200
Why?
Intimate Partner Violence
1
2016
2
0.200
Why?
Hypertension
1
2018
206
0.190
Why?
Lymph Node Excision
1
2016
107
0.180
Why?
Genomics
1
2016
89
0.180
Why?
Pilot Projects
1
2016
228
0.180
Why?
Poly (ADP-Ribose) Polymerase-1
1
2015
5
0.180
Why?
Early Detection of Cancer
1
2016
87
0.180
Why?
Clinical Trials, Phase II as Topic
1
2015
17
0.180
Why?
Cross-Sectional Studies
2
2016
516
0.180
Why?
Patient Acceptance of Health Care
1
2016
61
0.180
Why?
Lymph Nodes
1
2016
113
0.180
Why?
Drug Evaluation, Preclinical
1
2015
50
0.180
Why?
Diagnosis, Differential
1
2016
308
0.180
Why?
Administration, Oral
1
2015
119
0.180
Why?
Thrombophlebitis
1
2014
4
0.170
Why?
Palliative Care
1
2015
62
0.170
Why?
Receptors, Progesterone
1
2013
12
0.170
Why?
Postoperative Care
1
2014
51
0.170
Why?
Preoperative Care
1
2014
58
0.170
Why?
Receptors, Estrogen
1
2013
19
0.170
Why?
Histocytochemistry
1
2013
23
0.170
Why?
Quality of Life
1
2016
249
0.170
Why?
Health Facilities
1
2013
5
0.160
Why?
Tomography, X-Ray Computed
1
2017
428
0.160
Why?
Overweight
1
2014
71
0.160
Why?
Demography
1
2013
81
0.160
Why?
Length of Stay
1
2014
163
0.160
Why?
Academic Medical Centers
1
2013
58
0.160
Why?
Surgical Wound Infection
1
2014
67
0.160
Why?
Multivariate Analysis
1
2014
266
0.160
Why?
Fever
1
2013
33
0.160
Why?
Ablation Techniques
1
2013
14
0.160
Why?
Papanicolaou Test
1
2013
23
0.160
Why?
Continental Population Groups
1
2013
84
0.160
Why?
Vagina
1
2013
27
0.160
Why?
Vaginal Smears
1
2013
40
0.160
Why?
Breast Neoplasms
1
2018
406
0.150
Why?
Survival Analysis
1
2013
254
0.150
Why?
Ethnic Groups
1
2013
118
0.150
Why?
Brain Neoplasms
1
2015
185
0.150
Why?
Combined Modality Therapy
1
2013
272
0.150
Why?
Salpingectomy
1
2011
6
0.150
Why?
Predictive Value of Tests
1
2013
376
0.140
Why?
Severity of Illness Index
1
2013
316
0.140
Why?
Disease Progression
1
2013
315
0.140
Why?
Uterus
1
2011
20
0.140
Why?
Practice Patterns, Physicians'
1
2013
165
0.140
Why?
European Continental Ancestry Group
1
2013
429
0.140
Why?
African Americans
1
2013
343
0.130
Why?
Robotics
1
2010
46
0.130
Why?
Endoscopy
1
2010
56
0.130
Why?
Anti-Bacterial Agents
1
2013
299
0.130
Why?
Time Factors
1
2014
1165
0.120
Why?
Pregnancy
1
2012
600
0.120
Why?
Bronchiolitis Obliterans
1
2008
2
0.110
Why?
Graft Rejection
1
2008
28
0.110
Why?
Incidence
1
2008
399
0.100
Why?
Child
1
2008
1522
0.080
Why?
Animals
1
2015
6880
0.070
Why?
Tissue Array Analysis
1
2018
33
0.060
Why?
Evidence-Based Practice
1
2018
24
0.060
Why?
Gynecology
1
2018
31
0.060
Why?
Medical Oncology
1
2018
40
0.060
Why?
Vulnerable Populations
1
2018
26
0.050
Why?
Databases, Factual
1
2018
163
0.050
Why?
Platinum Compounds
1
2017
9
0.050
Why?
Neoplasm, Residual
1
2017
30
0.050
Why?
ROC Curve
1
2017
112
0.050
Why?
Peripheral Nervous System Diseases
1
2017
18
0.050
Why?
Platinum
1
2016
22
0.050
Why?
Taxoids
1
2017
40
0.050
Why?
Laparotomy
1
2016
28
0.050
Why?
Organoplatinum Compounds
1
2016
28
0.050
Why?
Ohio
1
2016
11
0.050
Why?
Thrombocytopenia
1
2017
92
0.050
Why?
Hospice Care
1
2015
8
0.050
Why?
Lymphatic Metastasis
1
2016
173
0.050
Why?
Drug Resistance, Neoplasm
1
2016
104
0.050
Why?
Radiotherapy, Adjuvant
1
2015
67
0.050
Why?
Decision Support Techniques
1
2015
41
0.040
Why?
Radiosurgery
1
2015
38
0.040
Why?
Male
1
2008
9220
0.040
Why?
Surveys and Questionnaires
1
2016
619
0.040
Why?
United States
1
2018
1647
0.040
Why?
Gunderson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_